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rior to surgery, and disinfection of the surgical site. Last,
ut not least, surveillance of SSIs is a well-established, well
ocumented approach to lower the incidence of SSIs. Many
ospitals still do not follow this recommendation despite
ts effectiveness. Endoscopy and robotic surgeries are new
evelopments that further help to keep rates of SSIs at
he lowest possible level. However, as patients leave the
ospital at a very early stage, post-discharge surveillance
ecomes mandatory. Many studies indicate that about 50%
f the SSIs undergo undetected unless postdischarge surveil-
ance is performed.
A lot of research has been performed in the last decade:
owever, many hospital still fail to implement these new
nowledge into clinical practice.
oi:10.1016/j.ijid.2008.05.082
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ultivalent Protection Against a Severe Pediatric Disease
Rotavirus
. Christie
University of the West Indies, Kingston, Jamaica
otaviruses are the foremost cause of severe gastroenteri-
is in young children, being responsible for 600,000 deaths,
million hospitalizations, 25million clinic visits, 111million
pisodes and 56% of hospitalizations for febrile gastroenteri-
is worldwide, each year. Every child is infected by age ﬁve
ears. RotateqTM is an oral, ready-to-use, 3-dose regimen
accine, containing 5 human-bovine reassortant rotavirus
erotypes given at 2, 4, 6 months of age, that is easily inte-
rated into pre-established immunization schedules. The
roduct has been studied in over 70,000 infants from all
ve continents. RotateqTM has proven efﬁcacy of 98% against
evere gastroenteritis for G1-4 strains, was well tolerated,
ncluding with respect to intussusception in prelicensure
nd postmarketing surveillance, with no increase in fever,
rritability, or hematochezia, while it reduced health care
ontacts for rotaviruses by nearly 100%. RotateqTM has FDA-
pproval and is now in use in 70 countries, with application
ending in another 75 countries, worldwide. RotateqTM is
owwidely available in USA, Canada, Australia, eleven coun-
ries in Europe, Latin America, the Caribbean and also in
ther parts of the world. RotateqTM is now in the review pro-
ess for WHO-prequaliﬁcation. Given the universal nature of
otavirus gastroenteritis, this vaccine is an extremely impor-
ant public health priority.
oi:10.1016/j.ijid.2008.05.083
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ong Term Beneﬁts of the Quadrivalent Human Papillo-
avirus Vaccine (HPV)
. Garland
The Royal Womens Hospital, Victoria, Australia
t is now realised that 99.7% of cervical cancers are caused
y oncogenic HPV infection: and worldwide HPV types 16 and
8 consistently account for 70% to 80% of cases. Moreover
PV types 16 and 18 contribute to 50% of high-grade dys-
lasias, and 25% of low-grade dysplasias. In addition, HPV is
he most common viral infection with condylomata accumi-
ata or genital warts (90% caused by HPV 6/11) being the
ost common viral sexually transmitted disease. Genital
arts peak in the mid-20 age group, commonly recur post-
reatment, and consequently are a costly burden in sexual
ealth settings, as well as causing signiﬁcant psychosocial
orbidity to those infected.
In phase III clinical trials of the quadrivalent human papil-
omavirus vaccine (6,11,16,18), vaccine HPV type-related
IN2/3, VIN 2/3 and VaIN 2/3 were used as surrogate
ndpoints in determining efﬁcacy against cervical, vulvar
nd vaginal cancers, respectively. Randomized, placebo-
ontrolled, double-blind trials involving more than 25,000
omen aged 15 - 26 years have shown up to 100% efﬁcacy
gainst HPV 6, 11, 16 and 18 related CIN2/3, AIS (adenocar-
inoma in situ), VIN, VaIN, as well as genital warts. Through
years of follow-up, the clinical efﬁcacy was maintained
ith no breakthrough cases observed in the vaccine group.
nmid adult women aged 24 - 45, the efﬁcacy of quadrivalent
PV vaccine in the prevention of HPV6/11/16/18-related
IN or external genital lesions (EGL) was 92.4%, with efﬁcacy
gainst HPV16/18-related CIN or EGL being 87.8%. Efﬁcacy
gainst HPV6/11-related CIN or EGL was 100%.
In all studies, vaccine was generally well-tolerated,
ith a signiﬁcant but slightly higher proportion of subjects
eporting one or more injection site adverse experiences
han the placebo group.
oi:10.1016/j.ijid.2008.05.084
8.003
alue of the Quadrivalent HPV Vaccine
.L. Villa
Ludwig Institute for Cancer Research, Brazil
accines provide long-term protection by inducing immune
emory - the ability to rapidly produce high antibody lev-
ls on subsequent encounters with pathogens targeted by
he vaccine. Prophylactic administration of a quadrivalent
PV (types 6/11/16/18) L1 VLP vaccine (GARDASIL®, Merck
Co., Inc.) to 16- to 23-year-olds was 96% effective in
reventing HPV 6/11/16/18 persistent infection or related
isease through 5 years of follow-up (Villa et al., Br J Cancer,
006). Sustained efﬁcacy against disease was maintained
ith no breakthrough cases of HPV 6, 11, 16 or 18-related
nfection or disease. In the same study, at the 5 year mark,
n antigen challenge was given that demonstrated that
ARDASIL® (formulated on a proprietary aluminum adju-
ant) had induced immune memory, a hallmark of vaccines
